SCHEMBL29896155

SCHEMBL29896155

Cc1ccncc1CNC(=O)c1ccc(OC(F)(F)F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 8/20 0.49
▸ PIK3CA P42336 1/20 0.47
▸ SCN3A Q9NY46 4/20 0.44
▸ ROCK1 Q13464 2/20 0.44
▸ HSD17B13 Q7Z5P4 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ABL1 P00519 1/20 0.42
▸ EPHX2 P34913 2/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ SCN1A P35498 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ SCN5A Q14524 1/20 0.42
▸ SCN9A Q15858 1/20 0.42
▸ SCN2A Q99250 1/20 0.42
▸ SCN8A Q9UQD0 1/20 0.42
▸ SCN10A Q9Y5Y9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27188856 1.00 ROCK2 (0.49) ROCK2PIK3CASCN3AROCK1HSD17B13
SCHEMBL29896178 0.88 ROCK2 (0.50) ROCK2SCN3AROCK1USP2ALDH1A1
SCHEMBL27188815 0.88 ROCK2 (0.50) ROCK2SCN3AROCK1USP2ALDH1A1
SCHEMBL27188863 0.88 L3MBTL1 (0.53) ROCK2PIK3CAROCK1USP2ALDH1A1
SCHEMBL29896151 0.88 L3MBTL1 (0.53) ROCK2PIK3CAROCK1USP2ALDH1A1
SCHEMBL29896165 0.85 ROCK2 (0.44) ROCK2PIK3CAROCK1HSD17B13EPHX2
SCHEMBL27188903 0.85 ROCK2 (0.44) ROCK2PIK3CAROCK1HSD17B13EPHX2
SCHEMBL27188834 0.85 PIK3CA (0.47) ROCK2PIK3CAUSP2ALDH1A1NPSR1
SCHEMBL29896120 0.85 PIK3CA (0.47) ROCK2PIK3CAUSP2ALDH1A1NPSR1
SCHEMBL27188851 0.85 ROCK2 (0.47) ROCK2SCN3AROCK1HSD17B13ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952344-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-04-09 — — US disclosed
US-20220340527-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340527-A1 HETEROCYCLIC COMPOUND AND USE THEREOF GRIN1, GRIN2A, GRIN2B ROCK2 4595/4885PIK3CA 3041/4885SCN3A 43/4885
US-11952344-B2 Heterocyclic compound and use thereof GRIN1, GRIN2A, GRIN2B ROCK2 4595/4885PIK3CA 3041/4885SCN3A 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback